Bacterial Vaginosis Linked to Cervical Intraepithelial Neoplasia

OncologyONCOLOGY Vol 9 No 4
Volume 9
Issue 4

Bacterial vaginosis, the most widespread vaginal infection in the United States, is associated with a 357% increase in the incidence of cervical intraepithelial neoplasia (CIN), an abnormality of cervical

Bacterial vaginosis, the most widespread vaginal infection in the United States, is associated with a 357% increase in the incidence of cervical intraepithelial neoplasia (CIN), an abnormality of cervical cells that may lead to cervical cancer, according to a study published in the Scandinavian journal Acta Obstetricia et Gynecologica Scandinavica.

Cervical cancer is believed to be the most common form of cancer in women worldwide. While screening with Pap smears has dramatically reduced the incidence of this cancer in the United States, an estimated 2.5 million American women are diagnosed with low-grade cervical cytologic abnormalities each year.

According to a retrospective evaluation of Pap smears obtained in 6,150 women, reported by Dr. Jens Platz-Christensen and colleagues at Sahlgrenska University Hospital in Goteborg, Sweden, bacterial vaginosis was diagnosed, by detection of clue cells in Pap smears, in 617 (10%) of the patients. Cervical intraepithelial neoplasia was found in 5% of these women with vaginosis, as compared with 1.4% of the women without vaginosis. Moreover, when early-stage CIN was excluded, second- and third-stage CIN occurred in 2.9% of the patients with bacterial vaginosis but in only .4% of those without this infection.

"The possibility exists that bacterial vaginosis is in some way associated with the development of cervical intraepithelial neoplasia," the authors conclude, noting that bacterial vaginosis may be a cofactor to the potentially cancer-causing human papillomavirus (HPV). The association between HPV and the development of CIN and cervical cancer is well documented. The abnormal vaginal flora in bacterial vaginosis can produce nitrosamines. These carcinogens may act synergistically with HPV to damage epithelial cells, thus aiding in the development of CIN.

A growing body of scientific evidence has also linked bacterial vaginosis with an increased risk of pelvic inflammatory disease, as well as cervicitis, endometritis, recurrent urinary tract infections, postoperative infection, and other health complications. Because of this mounting evidence, an increasing number of physicians advocate screening for bacterial vaginosis as part of the routine gynecologic examination. They note that, while a traditional Pap smear alone is unreliable for detection of this condition, simple office test procedures for bacterial vaginosis and other vaginal infections can be conducted in less than 3 minutes.

Clinical signs of bacterial vaginosis include a foul or fishy odor of varying degrees; a thin, milk-like discharge; a vaginal pH exceeding 4.5; and the presence of clue cells (epithelial cells coated with bacteria) in vaginal cultures.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content